

Online supplement table. Study design and demographic and outcome data of included studies

Rule	Year	Location (FN episodes)	Type	Age	Male sex n (%)	Haem malig n (%)	Relapse disease n (%)	CVAD <i>in situ</i> n (%)	Bacter- aemia n (%)	Death n (%)
Validation cohort(10)	2011-15	Australia (650 in 327 pts)	Retrospective single centre	Median 5.9y (IQR 3.5-10.3)	327 (50.3)	412 (63.4)	52 (8)	620 (95.4)	61 (9.4)	2 (0.3)
SPOG(9)	2004-07	Switzerland & Germany (423 in 206 pts)	Prospective multicentre	Median 6.9 (IQR 3.8-11.6)^	116 (56.3)^	129 (62.6)^	25 (12.1)^	NR	67 (15.8)*	3 (0.7)
Hakim(21)	2004-05	USA (332)	Retrospective single centre	Median 6y (range 0.2-21.6y)	182 (54.8)	218 (65.7)	60 (18)	317 (95.5)	41 (12.4)	0

Alexander (22)	1995	USA (188 in 104 pts)	Retrospective single centre	Mean 8.9y (SD 5.7)	56 (53.8)^	54 (51.9)*^	NR	NR	13 (12.5)^	1 (1)^
Baorto(23)	1990- 96	USA (1171)	Retrospective multicentre	Mean 7.8- 9.3y	NR	NR	NR	NR	189 (16.1)*	3 (0.3)
Klaassen(24)	1996- 97	Canada (227)	Prospective single centre	Median 6.8y (range 0.5-17)	111 (48.9)	129 (56.8)	22 (9.7)	194 (85.5)*	28 (12.3)	1 (0.4)
Rackoff(25)	1995- 95	USA (115)	Prospective single centre	(range 0.8-18y)	NR	48 (41.7)*	32 (27.8)	112 (97.4)	24 (20.9)*	NR

SPOG, Swiss Paediatric Oncology Group; NR, not recorded; CVAD, central venous access device; Haem malig, haematological malignancy;

Pts, patients. *Significant difference compared to validation cohort ($p < 0.05$); ^calculated from number of patients with FN